LP250847-3
Certolizumab
Active
Description
Certolizumab is a monoclonal antibody conjugated to polyethylene glycol used to treat Crohn's Disease (CD) and rheumatoid arthritis (RA). Certolizumab pegol binds to tumor necrosis factor alpha (TNFα), a pro-inflammatory cytokine that is implicated in the pathogenesis of a number of immunological diseases including CD and RA. TNFα mediates the signature inflammation-induced joint damage in RA. The reduction of TNFα alleviates symptoms of RA, CD and other immunologic diseases. TNFα-inhibitors have been hugely successful in treating immunological diseases. In spite of the positive impact TNFα-inhibitors have had there is still variability in response to their use including loss of response over time and drug tolerance. PMID: 20190560 Source: Regenstrief LOINC
Basic Part Properties
- Part Display Name
- Certolizumab
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2017-05-09
- Construct for LOINC Short Name
- Certolizumab
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP250847-3
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| it-IT | Italian (Italy) | Certolizumab pegol Synonyms: Certolizumab pegolo |
| es-ES | Spanish (Spain) | Certolizumab |
| zh-CN | Chinese (China) | 塞妥珠单抗 Synonyms: 塞妥珠单克隆抗体; |
| nl-NL | Dutch (Netherlands) | certolizumab |
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright